Citations

Clear

7542 citation(s) found for "Ho, Matthew".

Cultivating a Quality Improvement Culture With Mayo Clinic Quality Academy
Rohila, Vriddhi, Reyes, Chloe, Lawrence, Ashley, Phan, Hiliary, Gomes, April M., Ma, Chendong , Cox, Matthew D, Tan, Nelly , Cox, Matthew D. , Franco, Pablo Moreno

Mayo Clinic

American Journal of Medical Quality | April 10, 2026 | Volume: 41 | Issue: 3 | Pages: 133-138

10.1097/jmq.0000000000000298 | PMID 41961077 Get It

We examined outcomes of a quality improvement (QI) culture implemented through Mayo Clinic Quality Academy by retrospectively reviewing data from QI projects credited from 2019 to 2024. Data analyzed included roles, member count, region, project details, priorities, financial outcomes, methodologies, and lessons learned. During the study period, Mayo Clinic Quality Academy credited 1106 projects involving 10 063 members (median, 8 members per project). Physicians participated in 52.4% of projects, allied health professionals in 83.6%, and nurses in 55.2%. Among all projects, teamwork (54.0%) and efficiency (52.8%) were the most common organizational priorities; among National Academy of Medicine priorities, efficiency was the most common (32.2%), followed by safety (20.7%) and patient-centeredness (18.9%). Model for improvement was the most prevalent QI methodology (29.2%). Most participants (93%) believed the QI project changed the way they work. Cultivating a QI culture influences health care delivery by emphasizing efficiency, teamwork, operational performance, patient outcomes, satisfaction, and financial benefits.
Precision Diagnostics in Prostate Cancer Treatment (PREDICT): A Phase II Multiarm Biomarker-Based Study (Alliance A032102)
Chen, Yu‐Wei , Bobek, Olivia , Heller, G., Berg, S., Tan, Alan , Zhao, Shuang G. , Galsky, Matthew D. , Beltran, Himisha , McKay, Rana R. , Berg, Stephanie , Berg, Stephanie A , Zhao, Shuang G , Galsky, Matthew D , Rosenberg, Jonathan E , Beltran, Himisha , McKay, Rana R , Bobek, Olivia , Heller, Glenn , Chen, Yu-Wei

Mayo Clinic

JCO Oncology Advances | April 9, 2026 | Volume: 3 | Issue: 2 | Pages: No page available

10.1200/oa-25-00187 | PMID 42232816 Get It

Non–Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology
Riely, Gregory J. , Wood, Douglas E. , Aisner, Dara L. , Bauman, Jessica R. , Bharat, A., Chang, Joe Y., Desai, Aakash, Dilling, Thomas J. , Durm, Gregory A. , Gettinger, S., Gubens, Matthew A. , Lackner, Rudy P., Levy, B., Loo, Billy W., Maldonado, Fabien, Morgensztern, Daniel , Mullikin, Trey C. , Ng, Thomas, Owen, Dawn, Patil, Tejas, Riess, Jonathan W. , Mendez, Ana Lucia Ruano, Shapiro, Theresa A. , Singh, Aditi P., Stevenson, James, Tam, A. , Yau, Edwin , Gregory, Kristina, Hang, Lisa E., Desai, Aakash , Desai, Aakash P , Axtell, Andrea L. , Bharat, Ankit , Dowell, Jonathan E. , Gettinger, Scott , Grotz, Travis E. , Juloori, Aditya , Lanuti, Michael D. , Lin, Jules , Loo, Billy W. , Lovly, Christine Marie , Maldonado, Fabien , Ng, Thomas, Owen, Dwight H , Patil, Tejas , Polanco, Patricio Marcelo , Tanvetyanon, Tawee , Yanagawa, Jane , Yun, Karen M. , Gregory, Kristina M.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | April 9, 2026 | Volume: 24 | Issue: 4 | Pages: No page available

10.6004/jnccn.2026.0017 | PMID 41956107 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) provide recommendations for the treatment of patients with NSCLC, including diagnosis, primary disease management, surveillance, and subsequent treatment. The panel has updated the list of recommended targeted therapies based on recent FDA approvals and clinical data. This selection from the NCCN Guidelines for NSCLC focuses on treatment recommendations for advanced or metastatic NSCLC with actionable biomarkers.
Comparison of Emergency Department Attendance After Emergency Care Recommendations from Nurse and Online eHealth Self-Triage
Curry, Elizabeth , North, F. J., Pecina, Jennifer , Miller, Nathaniel E. , North, Frederick, Thompson, Matthew C , Pecina, Jennifer L.

Mayo Clinic

Telemedicine and e-Health | April 9, 2026 | Volume: 32 | Issue: 7 | Pages: 722-729

10.1177/15305627261440766 | PMID 41954037 Get It

Introduction: Online self-triage is a newer eHealth modality, and there is a paucity of research on patient adherence to self-triage recommendations. We evaluated patient compliance with online self-triage guidance to seek emergency care and compared to nurse-triage adherence rates. Methods: We reviewed primary care empaneled patients who had either nurse phone triage or an online self-triage encounter that resulted in an emergency care recommendation between January 1, 2023, and November 30, 2024. Patients triaged for mood concerns, abdominal pain, chest pain, constipation, cough, and diarrhea were included. We reviewed whether patients had an emergency department visit within 24 h of their triage encounter. For self-triage encounters, we also examined whether patients called nurse triage within 24 h of their self-triage encounter. Results: There were 689 self-triage and 2,385 nurse triage encounters with an emergency care endpoint. Adherence to the emergency care recommendation was substantially lower after self-triage (22%) than after nurse triage (61%). Patients who underwent nurse triage were significantly more likely to seek emergency care than those who self-triaged (odds ratio of 5.4 [95% CI: 4.5–6.6] p < 0.001). Both male and female patients were less likely to follow emergency care recommendations after self-triage compared to nurse triage ( p < 0.001). There were 258 patients with an emergency care endpoint from self-triage who chose to call nurse triage (median time between encounters of 16 min). Only 78 (30.2%) also received an endpoint recommendation for emergency care, and 73% of those patients sought emergency care within 24 h. Discussion: Patient compliance with online self-triage recommendations to seek emergency care was poor and significantly less than nurse triage. Follow-up calls to nurse triage led to higher compliance. Health systems using online symptom checkers should consider employing mechanisms to follow up on emergency care recommendations. Further research should elucidate factors that contribute to patients’ willingness to follow care recommendations.
Current Evidence on Medical Therapy for Sporadic Vestibular Schwannoma: A Systematic Review and Meta-analysis
Khandalavala, Karl R. , Marinelli, John P. , Lohse, Christine M., Carlson, Matthew L., Zalaquett, Nader G., Epperson, Madison V. , Zalaquett, Nader , Epperson, Madison V. , Lohse, Christine M. , Chelf, Cynthia , Carlson, Matthew L.

Mayo Clinic

Otology & Neurotology | April 9, 2026 | Volume: 47 | Issue: 6 | Pages: 846-852

10.1097/mao.0000000000004904 | PMID 41952108 Get It

Objective: To systematically review studies evaluating systemic medical therapies for sporadic vestibular schwannoma (VS) and perform meta-analyses to assess associations with tumor control. Study design: Systematic review and meta-analysis. Setting: Not applicable. Patients: Sporadic VS patients. Interventions: Systemic medical therapies. Main outcome measures: Tumor growth. Results: Nine retrospective studies met criteria: 5 on nonsteroidal anti-inflammatory drugs (NSAIDs), 3 on metformin, and 1 on losartan (all level 3 evidence). A meta-analysis of ORs from 5 studies demonstrated no significant association between aspirin use and tumor growth (pooled OR: 0.77; 95% CI: 0.48-1.23; I²: 76%). Conversely, a meta-analysis of ORs from 3 studies on metformin showed significantly lower odds of tumor growth (pooled OR: 0.46; 95% CI: 0.30-0.72; I²: 0%). The study on losartan did not identify a statistically significant association of losartan with tumor growth. Less than half of the studies reported HRs to appropriately reflect the inherently time-dependent nature of tumor growth. Conclusions: Evidence for systemic therapies in sporadic VS remains preliminary. Our meta-analysis of ORs demonstrates that NSAID use is not significantly associated with tumor growth, metformin users had lower odds of tumor growth, and evidence for losartan remains limited; however, all available studies provide only level 3 evidence. At present, there is insufficient data to recommend routine use of aspirin, metformin, or losartan with the intent of mitigating VS tumor growth during wait-and-scan management. High-quality prospective studies with appropriate time-to-event methodology to assess tumor growth are required to establish the clinical utility of systemic therapies in the management of patients with sporadic VS.
Petrous Apex Chondrosarcoma With Postobstructive Tympanomastoid Cholesterol Granuloma: Why T1 Precontrast Sequences Still Matter
Link, Michael J., Lane, John I. , Carlson, Matthew L., Epperson, Madison V. , Link, Michael J. , Carlson, Matthew L.

Mayo Clinic

Otology & Neurotology | April 9, 2026 | Volume: 47 | Issue: 6 | Pages: e886-e887

10.1097/mao.0000000000004913 | PMID 41952100 Get It

Donor-derived Cell-free DNA for Detection of Rejection After Pancreas Transplantation
Matar, Abraham J. , Sarumi, Heidi, Finger, Erik, Humphreville, Vanessa , Ramanathan, Karthik, Fisher, J. Elwood, Rao, J. Sunil , Prewett, Adam , Tabriziani, Hossein , Kandaswamy, Raja, Megaly, Michael S. , Riad, Samy , Sarumi, Heidi , Megaly, Michael , Wright, Matthew, Finger, Erik, Ramanathan, Karthik V. , Fisher, Jessica, Demko, Zachary P , Kandaswamy, Raja

Mayo Clinic

Transplantation Direct | April 8, 2026 | Volume: 12 | Issue: 5 | Pages: e1939

10.1097/txd.0000000000001939 | PMID 41972229 Get It

Background. Donor-derived cell-free DNA (dd-cfDNA) has emerged as a promising noninvasive biomarker for detecting allograft rejection in solid organ transplantation. However, its diagnostic utility in pancreas transplantation, including in multiorgan recipients, remains underexplored. Methods. We conducted a retrospective analysis of 42 pancreas transplant recipients (38 simultaneous pancreas-kidney, 4 pancreas transplant alone) who underwent for-cause organ biopsy and dd-cfDNA testing between April 2020 and December 2024. dd-cfDNA was measured using the Prospera assay, with a threshold of ≥1% considered high risk and <1% low-risk. Biopsy results were correlated with dd-cfDNA to assess test performance. Results. A total of 50 dd-cfDNA tests and 45 organ biopsies were analyzed. Among simultaneous pancreas-kidney recipients, dd-cfDNA demonstrated a sensitivity of 86.7%, specificity of 52.2%, positive predictive value (PPV) of 54.2%, and negative predictive value (NPV) of 85.7% for rejection. In pancreas transplant alone recipients, all high-risk dd-cfDNA results corresponded to biopsy-proven rejection, yielding 100% sensitivity, specificity, PPV, and NPV. When combining both cohorts, dd-cfDNA testing achieved an overall sensitivity of 88.2%, specificity of 57.7%, PPV of 57.7%, and NPV of 88.2%. Additionally, dd-cfDNA kinetics suggested its potential utility as a surveillance tool posttreatment, potentially reducing the need for closure biopsies. Conclusions. dd-cfDNA is a valuable noninvasive adjunct for monitoring of rejection in pancreas transplant recipients. Further prospective studies are needed to validate these findings and define the optimal role of dd-cfDNA in posttransplant care.
Technology Dependence in Educational Practice: Evaluating the Scientific and Practical Impacts
Byrne, Matthew , Byrne, Matthew D., Byrne, Matthew D.

Mayo Clinic

Nursing Education Perspectives | April 7, 2026 | Volume: 47 | Issue: 3 | Pages: 201-201

10.1097/01.nep.0000000000001533 | PMID 41943206 Get It

Clinical significance of anti‐M in pregnancy and self‐reported ancestry: The BEST collaborative study
Lu, Wen , Ziman, Alyssa , Yan, M. T. S., Virk, Mrigender , Stephens, Laura D. , Radwi, Ghazala, Morrison, Douglas, Marrero‐Rivera, Gisela , Ly, Judy , Ikeda, Kazuhiko, Hands, Katie , Malti, Salwa El, Eichbaum, Quentin , Covello, Thomas, Chang, Shelley, Brancamp, Rachel , Badawi, Maha, AlMozain, Nour, Shan, Hua , Collaborative, The Biomedical Excellence for Safer Transfusion, AlMozain, Nour , Yin, Charles , Yan, Matthew T S , Stephens, Laura , Marrero-Rivera, Gisela , Hasan, Rida A , Clarke, Gwen , Bakhtary, Sara , Badawi, Maha , Ziman, Alyssa , Lu, Wen , Almozain, Nour , Raval, Jay S. , Radwi, Ghazala , Ly, Jane, Juskewitch, Justin E. , Ikeda, Kazuhiko, Hasan, Rida A. , Duncan, Jennifer, Bakhtary, Sara , Au, Nicholas H. C.

Mayo Clinic

Transfusion | April 6, 2026 | Volume: 66 | Issue: 6 | Pages: 1086-1098

10.1111/trf.70210 | PMID 41937612 Get It

Abstract Background Anti‐M antibodies were described as rarely eliciting hemolytic disease of the fetus and newborn (HDFN) in pregnancy. More recent literature, primarily from Asia, reports severe HDFN attributed to maternal anti‐M. The objective of this study is to determine if there is a difference in the frequency and/or severity of anti‐M HDFN among subjects who self‐report as Asian compared to non‐Asian. Methods Retrospective data were collected from 18 sites. Fetuses/neonates affected by HDFN were categorized as unaffected, mild, moderate, or severe based on clinical management and outcomes. Results Anti‐M was identified in 557 obstetric patients. Among 332 neonates with complete data for analysis, anti‐M was detected in isolation during the pregnancies of 210 (63.3%) neonates; 198 (94.3%) were unaffected by HDFN. The overall frequency of HDFN was 6.5% (2/31) in Asian patients and 5.6% (10/179) in non‐Asian patients. The frequency of severe HDFN was 6.5% (2/31) among Asian patients and 0.6% (1/179) among non‐Asian patients. Among non‐Asian patients, eight (4.5%) were mild and one (0.6%) was moderate. Of 63 pregnancies with anti‐M and ABO incompatibility, 6 (9.5%) were associated with mild HDFN and 57 (90.5%) were unaffected. Of 49 pregnancies with anti‐M and non‐ABO antibody(s), 6 (12.2%) were associated with mild HDFN and 43 (87.8%) were unaffected. One case (10.0%) of HDFN (mild) occurred in the presence of anti‐M, additional antibody(s), and ABO incompatibility. Conclusion In this study, severe anti‐M HDFN was rare in non‐Asian subjects. There is a signal that Asian patients are at greater risk for severe anti‐M HDFN.
Sex-based Differences in Quality of Life for Sporadic Vestibular Schwannoma Patients Managed With Observation, Microsurgery, or Radiation
Zalaquett, Nader , Lohse, Christine M., Link, Michael J., Carlson, Matthew L., Zalaquett, Nader G., Zalaquett, Nader , Lohse, Christine M. , Link, Michael J. , Carlson, Matthew L.

Mayo Clinic

Otology & Neurotology | April 3, 2026 | Volume: 47 | Issue: 6 | Pages: e856-e860

10.1097/mao.0000000000004906 | PMID 41931635 Get It

Objective: Quality of life (QOL) is an important consideration in vestibular schwannoma (VS) patients when assessing management options. Understanding sex-based differences in QOL may facilitate patient counseling. Study design: Prospective cohort. Setting: Tertiary academic medical center and Acoustic Neuroma Association. Patients: Sporadic VS patients. Interventions: Observation, microsurgery, or radiation. Main outcome measures: Penn Acoustic Neuroma Quality of Life (PANQOL) scores. Results: A total of 481 patients were analyzed. In the observation group, women reported worse anxiety, facial function, and total PANQOL scores at baseline. At follow-up, men declined more in facial function (−5 vs. +3, P =0.01). For microsurgery, women reported worse facial function and balance scores at baseline. At follow-up, men declined more in facial function (−16 vs. −3, P <0.001), balance (−7 vs. +2, P =0.04), energy (−4 vs. +5, P =0.03), and total (−5 vs. +2, P =0.02) PANQOL scores. For radiation, women reported worse anxiety, balance, pain, and total scores at baseline. At follow-up, anxiety improved in women but worsened in men (+5 vs. −6, P =0.008). Sex-based differences exceeding the minimally important difference thresholds established for the PANQOL were observed for the following: anxiety at baseline in the observation group, anxiety and pain at baseline in the radiation group, and change in anxiety from baseline to follow-up in the radiation group. Conclusions: Women had worse anxiety, balance, facial function, pain, and overall QOL at baseline assessed using the PANQOL, whereas men declined more with treatment and observation. The largest difference in PANQOL change between sexes occurred after microsurgery, with men experiencing greater losses in facial function, balance, energy, and total scores.